MorphoSys to Present Data on Proprietary Programs at 20th Congress of the European Hematology Association

MARTINSRIED / MUNICH, Germany, May 21, 2015 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced the publication of three MorphoSys abstracts which were submitted to the 20th Congress of the European Hematology Association (EHA) to take place from June 11 - 14 in Vienna, Austria. The abstracts include pre-clinical and clinical data on the Company's proprietary drug candidate MOR202 from a Phase 1/2a study in patients with multiple myeloma and updated clinical data for the MOR208 program.

"The progress of our cancer compounds MOR202 and MOR208 is increasingly gaining visibility," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "We are looking forward to presenting our most advanced cancer programs at the EHA congress, including efficacy data for MOR202 from the Phase 1/2a study in multiple myeloma."

List of abstracts:

Abstract EHA-3357

A phase 1/2a study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma

The presentation will include the in the abstract described safety results and additional first efficacy results. The oral presentation will take place on Sunday, June 14, 09:00 - 09:15 am CEST.

Abstract EHA-3452

Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.

The poster presentation will take place on Saturday, June 13, 5:15 - 6:45 pm CEST.

Abstract #E990

A phase 2a study of single-agent MOR208, an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

The abstract will be on display on the e-poster screens from Friday, June 12, 09:30 am to Saturday, June 13, 6:45 pm CEST.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Manager Corporate Communications & IR

Jessica Rush
Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404

Media Release (PDF)


Source:MorphoSys AG